Machine-Learning-Based Prediction of Long-Term Efficacy of Nemolizumab: Post Hoc Analysis of Pooled Data from Two Phase III Clinical Trials - PubMed
3 days ago
- #Machine Learning
- #Atopic Dermatitis
- #Nemolizumab
- Nemolizumab targets interleukin-31 receptor to reduce pruritus in atopic dermatitis.
- Machine learning identified key predictors of long-term efficacy in patients without early improvement.
- Top predictors: no worsening of AD/other skin disorders by week 16 and mean itch score <2.1 at week 16.
- Model achieved an F1 score of 0.737 using pooled data from two Japanese Phase III trials.
- Findings support clinical decisions on continuing nemolizumab treatment beyond 16 weeks.